This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Avricore Health Closes $1.254M Financing
Business private placement

Avricore Health Closes $1.254M Financing

Analysis based on 8 articles · First reported Jun 17, 2026 · Last updated Jun 17, 2026

Sentiment
60
Attention
2
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The successful private placement by Avricore Health is expected to positively impact its stock price due to strengthened capital for UK expansion and growth. The financing provides the company with the necessary funds to execute its strategic plans, potentially leading to increased revenue and market share in the healthcare sector.

Healthcare Biotechnology
Event Summary

Avricore Health has successfully closed a non-brokered private placement, raising gross proceeds of $1,254,000 through the issuance of 25,080,000 Units at $0.05 per Unit. This financing, which included participation from insiders, is intended to provide Avricore Health with the capital strength for its UK expansion and general working capital purposes. Canaccord Genuity received finders fees and warrants for its role. The closing is subject to final acceptance by the TSX Venture Exchange, and all securities issued are subject to a four-month hold period under Canadian securities laws. Rodger Seccombe, CEO of Avricore Health, emphasized that this funding will support the company's growth strategy, particularly for its HealthTab offering, which focuses on point-of-care testing networks.

Entities Involved
stock
Avricore Health
Avricore Health successfully closed a private placement, raising $1,254,000, which will be used for its UK expansion and general working capital, strengthening its financial position and supporting its growth strategy.
Importance 100.0 Sentiment 70.0
per
Rodger Seccombe
Rodger Seccombe, as CEO of Avricore Health, expressed appreciation for investor commitment and highlighted the financing's role in the company's UK expansion and growth strategy.
Importance 70.0 Sentiment 60.0
stock
Canaccord Genuity
Canaccord Genuity acted as an arm's length finder for the private placement, receiving finders fees and warrants.
Importance 30.0 Sentiment 20.0
exch
TSX Venture Exchange
The TSX Venture Exchange is the regulatory body that needs to provide final acceptance for the private placement to be fully complete.
Importance 20.0 Sentiment 0.0
priv
CEQAL Inc.
CEQAL Inc. is a partner of HealthTab, contributing to its quality management program, ensuring high standards of analytical performance and reliability.
Importance 10.0 Sentiment 0.0
govactor
United States — Centers for Disease Control and Prevention
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.